Validation of ClarityDX Prostate as a Reflex Test to Refine Prediction of Clinically Significant Prostate Cancer: ClinicalTrials.gov ID: NCT03957252

Summary

This study is designed to determine the accuracy of the blood test ClarityDX Prostate to predict the results of prostate biopsies in men who have PSA (Prostate Specific Antigen) greater than 3 and no higher than 10 ng/mL.